Jones David Scott 4

Accession 0001562180-24-000673

CIK 0001314102other

Filed

Jan 25, 7:00 PM ET

Accepted

Jan 26, 5:03 PM ET

Size

25.5 KB

Accession

0001562180-24-000673

Form 4

Period: 2024-01-24

SVP & Chief Commercial Officer

Transactions

Exercise/Conversion
Common Stock
2024-01-24$3.26/sh+5,700$18,582→ 49,262 total
Sale
Common Stock
2024-01-24$25.01/sh−5,600$140,068→ 37,962 total
Sale
Common Stock
2024-01-25$25.00/sh−300$7,500→ 38,262 total
Sale
Common Stock
2024-01-25$25.00/sh−300$7,500→ 37,962 total
Sale
Common Stock
2024-01-24$25.01/sh−5,700$142,554→ 43,562 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-01-25−300→ 18,325 total
Exercise: $12.90Exp: 2030-02-28→ Common Stock (300 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-01-24−5,700→ 85,455 total
Exercise: $3.26Exp: 2033-01-05→ Common Stock (5,700 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-01-25−300→ 85,155 total
Exercise: $3.26Exp: 2033-01-05→ Common Stock (300 underlying)
Exercise/Conversion
Common Stock
2024-01-25$12.90/sh+300$3,870→ 38,262 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-01-24−5,600→ 18,625 total
Exercise: $12.90Exp: 2030-02-28→ Common Stock (5,600 underlying)
Exercise/Conversion
Common Stock
2024-01-24$12.90/sh+5,600$72,240→ 43,562 total
Exercise/Conversion
Common Stock
2024-01-25$3.26/sh+300$978→ 38,562 total

Footnotes (4)

[F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.09. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
[F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.25. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
[F3]The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
[F4]The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

Documents

1 file

EyePoint Pharmaceuticals, Inc.

CIK 0001314102

Entity typeother